Net Cash Provided by (Used in) Financing Activities of Dianthus Therapeutics, Inc. /DE/ from 31 Dec 2016 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Dianthus Therapeutics, Inc. /DE/ annual and quarterly Net Cash Provided by (Used in) Financing Activities in USD history and change rate from 31 Dec 2016 to 31 Dec 2025.
  • Dianthus Therapeutics, Inc. /DE/ Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Mar 2025 was $161,000, a 100% decline year-over-year.
  • Dianthus Therapeutics, Inc. /DE/ annual Net Cash Provided by (Used in) Financing Activities for 2025 was $280,125,000, a 9.6% increase from 2024.
  • Dianthus Therapeutics, Inc. /DE/ annual Net Cash Provided by (Used in) Financing Activities for 2024 was $255,623,000, a 91% increase from 2023.
  • Dianthus Therapeutics, Inc. /DE/ annual Net Cash Provided by (Used in) Financing Activities for 2023 was $133,574,000, a 38% increase from 2022.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)

Dianthus Therapeutics, Inc. /DE/ Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $280,125,000 +$24,502,000 +9.6% 01 Jan 2025 31 Dec 2025 10-K 09 Mar 2026 2025 FY
2024 $255,623,000 +$122,049,000 +91% 01 Jan 2024 31 Dec 2024 10-K 09 Mar 2026 2025 FY
2023 $133,574,000 +$36,898,000 +38% 01 Jan 2023 31 Dec 2023 10-K 11 Mar 2025 2024 FY
2022 $96,676,000 +$81,764,000 +548% 01 Jan 2022 31 Dec 2022 10-K 21 Mar 2024 2023 FY
2021 $14,912,000 -$52,827,000 -78% 01 Jan 2021 31 Dec 2021 8-K 21 Dec 2023
2020 $67,739,000 +$5,442,000 +8.7% 01 Jan 2020 31 Dec 2020 10-K 08 Mar 2022 2021 FY
2019 $62,297,000 -$79,850,000 -56% 01 Jan 2019 31 Dec 2019 10-K 03 Mar 2021 2020 FY
2018 $142,147,000 +$70,661,000 +99% 01 Jan 2018 31 Dec 2018 10-K 03 Mar 2020 2019 FY
2017 $71,486,000 +$60,775,000 +567% 01 Jan 2017 31 Dec 2017 10-K 03 Mar 2020 2019 FY
2016 $10,711,000 01 Jan 2016 31 Dec 2016 10-K 19 Mar 2019 2018 FY

Dianthus Therapeutics, Inc. /DE/ Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $161,000 -$217,686,000 -100% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q1 2024 $217,847,000 +$217,847,000 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1
Q1 2023 $0 $0 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q1 2022 $0 -$418,000 -100% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q1 2021 $418,000 -$706,000 -63% 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022 2022 Q1
Q1 2020 $1,124,000 +$561,000 +100% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q1 2019 $563,000 +$738,000 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q1 2018 $175,000 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019 2019 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.